Platinum Priority – EditorialReferring to the article published on pp. 874–882 of this issuePractical Polling for Prostate Cancer: AR-V7–based Treatment Selection
Section snippets
Conflicts of interest
The authors have nothing to disclose.
References (16)
- et al.
Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer
Eur Urol
(2017) - et al.
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man
Cancer Cell
(2013) - et al.
Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer
Eur Urol
(2017) - et al.
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study
EBioMedicine
(2015) - et al.
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
N Engl J Med
(2014) - et al.
The transcriptional programme of the androgen receptor (AR) in prostate cancer
BJU Int
(2014) - et al.
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network
EMBO Mol Med
(2014) - et al.
Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype
Oncogene
(2014)
Cited by (3)
Liquid biopsy approach in the management of prostate cancer
2018, Translational ResearchCitation Excerpt :This study provides evidence that men with non-nuclear AR-V7 still exhibit some PSA responses to ARSis.39 The predictive capacity of an isolated CTC vs AR-V7 mRNA transcripts in a pooled sample are under evaluation in 2 independent validation studies for which reports are expected in near future.41 The role of AR-V7 as a treatment response biomarker is not only limited to ARSis.
Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists’ perspective
2017, Urological ScienceCitation Excerpt :Scher et al. have shown that approximately 20% of resistances can be identified using this method making it a promising means of non-invasive molecular profiling for mCRPC. However, it has not yet demonstrated an ability to surpass or complement the need for nuclear-specific protein localization.65,66 The treatment landscape continues to change.
The value of AR-V7 in predicting therapeutic efficiency of abiraterone for CRPC patients
2020, Chinese Journal of Urology